Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential

1

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show potential benefits in inflammatory bowel disease (IBD) through anti-inflammatory and gut barrier-enhancing effects.
2

Pre-clinical studies indicate that GLP-1RAs can reduce inflammation and preserve epithelial integrity in colitis models.
3

Early retrospective studies suggest that GLP-1RAs may improve clinical outcomes in IBD patients, particularly those with obesity.
4

The safety and pharmacokinetics of GLP-1RAs in IBD patients require further investigation due to potential gastrointestinal side effects.
5

This review highlights the need for prospective trials to evaluate the efficacy and safety of GLP-1RAs in the treatment of IBD.

Journal Of Crohn's And Colitis

by Michael Colwill, Sebastian Povlsen, Richard Pollok, Kamal Patel, James Goodhand, Tariq Ahmad, Sailish Honap
September 16, 2025

1